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Developing New Inhibitors of Intravascular Thrombosis*Neal S. Kleiman, MD,yz Kumaran Kolandaivelu, MD, PHDxk{I t is an axiom of Major League Baseball that “allprospects are suspect.” Many newly identiﬁedplayers seem promising initially but do not ulti-
mately develop into stars. However, all big-league
stars were prospects at one time, and new players
are needed to supplement teams and replace aging
athletes.
The situation is similar when it comes to car-
diovascular drugs, particularly antithrombotic ag-
ents. Some have succeeded, many have failed, and
others have not been widely adopted. Although
mortality related to atherosclerosis has fallen im-
pressively, clinicians must now choose from a bewil-
dering number of therapeutic choices for nearly every
clinical situation they face. When antithrombotic
drugs alone are considered in the setting of ST-
segment elevation myocardial infarction (MI), 96
potential combinations of antithrombotic drugs are
currently available, even before dose and duration
are considered. If cangrelor and low-dose rivarox-
aban receive federal approval, the number may
reach 384. An episode of atrial ﬁbrillation captured
on a telemetry monitor will push this ﬁgure well
beyond 800.
When a new drug is proposed, one cannot help but
wonder whether it is needed, how it will be evalu-
ated, how it will ﬁt into the current pharmacopeia,
and, most critically, how clinicians will determine*Editorials published in the Journal of the American College of Cardiology
reﬂect the views of the authors and do not necessarily represent the
views of JACC or the American College of Cardiology.
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disclose.that prescribing it is worthwhile. Nonetheless, new
“prospects” are needed in both hospital and outpa-
tient settings. For example, although rapid reperfu-
sion is widely practiced and door-to-balloon time has
fallen considerably, 30-day mortality for patients
with ST-segment elevation MI is still nearly 10% (1).
Among patients who were discharged alive after
acute coronary syndromes (ACS) and enrolled in
IMPROVE-IT (Improved Reduction of Outcomes:
Vytorin Efﬁcacy International Trial), nearly 15%
experienced MI, nearly 5% had strokes, and more
than 15% had died by the end of 7 years despite
aggressive lipid lowering (mean low-density lipopro-
tein cholesterol 53 mg/dl) (2).
Virtually all clinicians recognize the central role
of thrombosis in the acute manifestations of athero-
sclerotic vascular disease. However, clinicians are
often reluctant to adopt new antithrombotic drugs,
particularly when administered on top of existing
regimens. The new P2Y12 antagonists prasugrel and
ticagrelor offer more potent antiaggregation than
clopidogrel and are superior in preventing numerous
serious cardiovascular events after ACS presenta-
tion. Prasugrel was approved in 2009, ticagrelor in
2011. Estimates of their adoption vary, but are
disappointing. In the recent TOTAL (A Trial of
Routine Aspiration Thrombectomy With Percuta-
neous Coronary Intervention [PCI] Versus PCI Alone
in Patients With ST-Segment Elevation Myocardial
Infarction [STEMI] Undergoing Primary PCI) trial of
thrombectomy in patients with STEMI, slightly fewer
than one-third of patients were discharged on either
prasugrel or ticagrelor (3). The recent demonstration
that ticagrelor used with aspirin was superior to
aspirin alone for secondary prevention after MI raises
the likelihood that more patients will be treated with
aggressive dual-antiplatelet therapy (4).
Vorapaxar, a platelet protease–activated receptor
(the principal thrombin receptor) antagonist, was
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2417approved in late 2014 for secondary prevention in
peripheral artery disease or after MI. When added to a
background of aspirin (97% of patients) and clopi-
dogrel (71%), vorapaxar reduced the composite risk
for death, MI, or stroke in this population from 9.5%
to 7.9%, while moderate or severe bleeding (accord-
ing to the GUSTO [Global Utilization of Streptokinase
and Tissue Plasminogen Activator for Occluded Cor-
onary Arteries] criteria) was increased from 2.4% to
3.7% (5). How often vorapaxar will be used as a third
antithrombotic drug remains to be seen.SEE PAGE 2404Given the reluctance to compound medications, it
makes sense to search for new antithrombotic targetsFIGURE 1 GPVI Mechanisms and Applications
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In this issue of the Journal, Jamasbi et al. (6) report
signiﬁcant progress in assessing glycoprotein (GP) VI
antagonists as antithrombotic candidates. The semi-
nal role of platelet adhesion and activation in arterial
thrombosis on a disrupted endothelial surface has
been reviewed previously (7). GPVI, the primary
platelet receptor for collagen (8), recognizes a
glycine-proline-hydroxyproline motif on collagen
and facilitates platelet adhesion and activation,
particularly under low-shear conditions. On quies-
cent platelets, GPVI exists as a monomer. After
platelet activation, GPVI complexes cluster on the
platelet surface, and the cytoplasmic tails of adjacent
GPVI molecules become linked, causing GPVI toDimeric GPVI-Fc
• Rapidly binds exposed collagen locally
• Incomplete collagen site saturation
   at doses that saturate inhibitory effect
• Targeted high shear platelet inhibition
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to clinically approved antiplatelet agents. Although anti-GPVI antibodies that block monomeric
iting low and high shear platelet deposition, soluble dimeric GPVI-Fc (right, blue) selectively
g risk. Yet adding dimensions to balancing antithrombotic efﬁcacy and safety via triple-
egimens may further bend (or break) the scales of clinical complexity, with 96 permutations of
cardial infarction (STEMI) management before considering dose, duration, or other drugs on the
heparin.
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2418assume a dimeric conﬁguration that binds collagen
with greater afﬁnity than does the monomeric form
(9) (Figure 1).
GPVI is regarded as an attractive prospect for
several reasons. It is expressed only on megakaryo-
cytes and platelets, thus reducing the risk that its
inhibitors will have off-target effects. Increased GPVI
expression has been shown in patients with ACS (10)
and with ischemic stroke (11). GPVI also shares some
signaling pathways with GP Ib/IX/V. Thus, GPVI
blockade should theoretically allow von Willebrand
Factor–GP Ib/IX/V–mediated hemostasis to continue
(12). GPVI deﬁciency, whether acquired or congen-
ital, is often said to be associated with mild
bleeding, although of the 11 cases amassed by Arthur
et al. (13), 3 required transfusion, particularly in
relation to surgery (13).
Jamasbi et al. (6) chose 2 approaches to assess GPVI
blockade: blocking the collagen target for GPVI
binding and blocking the active site on GPVI itself.
For the former, they used a human Fc fusion protein,
GPVI-Fc (Revacept, AdvanceCOR GmbH, Munich,
Germany), which mimics the collagen-binding do-
main of GPVI. GPVI-Fc attaches to the gly-pro-hyp
motif of collagen that is recognized by GPVI, mask-
ing it from recognition by the platelet. Previously, in
a rabbit model of balloon injury, GPVI-Fc reduced
mural thrombus formation and preserved endothelial
function (14). In a study of healthy volunteers, it was
well tolerated and produced dose-dependent inhibi-
tion of collagen-induced platelet aggregation that
lasted 2 to 7 days, depending on the dose adminis-
tered (15). It is now in an exploratory trial of carotid
stenosis (NCT01645306).
Jamasbi et al. (6) compared this effect with direct
blockade of GPVI on the platelet surface using anti-
bodies directed at the monomeric and dimeric forms
of GPVI. They observed that in static blood, the anti-
GPVI antibodies inhibited platelet aggregation in-
duced by human carotid artery plaque homogenate
much more completely than did GPVI-Fc, even when
the latter was used at high doses (35- to 50-fold) with
extended periods of plaque pre-incubation (3 to
30 min).
However, under ﬂow conditions, the differences
narrowed at high shear rates. GPVI-Fc adhered in-
completely to a surface consisting of plaque ho-
mogenate, leaving small areas uncovered despite
high dosing. Under low shear, its effect on plaque-
induced platelet deposition was modest, but at
higher shear, it became considerably more effective.
The investigators inferred that at low shear, the
uncovered areas allowed collagen-induced plateletadhesion and activation, but under high shear,
platelets were washed off the collagen surface.
Conversely, the antibodies were effective at all shear
rates tested. The clinical implication is that cloaking
the collagen sites recognized by GPVI might offer a
safety advantage compared with that of complete
blockade of platelet GPVI, in that this process might
permit hemostasis to occur outside of stenotic
arteries.
These tantalizing observations offer the hope that
thrombosis and hemostasis may at last be uncou-
pled. Features of dimeric GPVI-Fc such as inhibitory
effect saturation without full inhibition of the GPVI-
collagen axis and inhibition that is localized to
sites of collagen exposure, in contrast to systemic
platelet inhibition, are certainly favorable in many
regards. How do we determine whether the GPVI
“prospect” is ready for prime time? Obviously, more
extensive characterization of GPVI blockade is
needed before such compounds are fully ready to
enter the pharmacologic armamentarium. The ap-
propriate degree and duration of blockade need to
be explored.
Background therapy must also be deﬁned. Indeed,
when the GPVI-Fc experiment was repeated with
the fusion protein in the presence of aspirin and a
P2Y12 antagonist, platelet aggregation was almost
completely eliminated, even at low shear (6). Will
GPVI blockade be clinically effective in the absence of
either of these drugs—or hazardous if used in their
presence? Omitting drugs from established thera-
peutic regimens is not an easy task, yet few will likely
use a GPVI antagonist if it is to be given as a third or
even fourth ingredient in a cocktail of antithrombotic
drugs.
It is clear that at some point, new antithrombotic
agentswill need to be tested as substitutes for accepted
drugs rather than simply additions to existing regi-
mens. Although aspirin has long been a mainstay
of pharmacotherapy for atherosclerotic disease, at
least 3 studies are under way to test the safety of
eliminating it fromACS or post–percutaneous coronary
intervention regimens (NCT02270242, NCT01776424,
and NCT02293395).
Simpliﬁcation and substitution: both of these steps
appear to be necessary parts of renewing our thera-
peutic roster.
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